Dr. Boothman received his PhD from the Department of Microbiology and Immunology at the University of Miami School of Medicine. After a post-doctoral fellowship at the Dana-Farber Cancer Institute, Harvard, he joined the Department of Radiation Oncology, University of Michigan, as an Assistant Professor. In 1993, he moved to the Department of Human Oncology at the University of Wisconsin, Madison, and was promoted from Assistant to Associate Professor, with tenure. In 1998, he became Professor of Pharmacology and Radiation Oncology, Case Western Reserve University, where he served as Associate Director for Basic Science, Case Western University Comprehensive Cancer Center. Currently, Dr. Boothman is Professor of Pharmacology and Radiation Oncology, Associate Director for Translational Research, Simmons Comprehensive Cancer Center, UT Southwestern at Dallas, where he also co-directs the “Program in Cell Stress and Cancer Nanomedicine” as well as ‘Experimental Therapeutics Program’ within the Simmons Comprehensive Cancer Center. Dr. Boothman has served on numerous peer-review study sections and has published more than 150 peer-reviewed papers. He holds the Robert B. and Virginia Payne Professorship in Oncology. His laboratory focuses on understanding cell stress responses and exploiting these for tumor-selective therapies. There are two main projects ongoing within his lab: (a) Exploiting elevated levels of the NAD(P)H:quinone oxidoreductase 1 (NQO1) for using unique NQO1 bioactivatable drugs for the treatment of pancreatic, lung, breast, prostate, head and neck and ATRT (pediatric) cancers.; and (b) Understanding and exploiting the functions of RNA transcription termination factors (Kub5-Hera (RPRD1B), p15RS (RPRD1A), XRN2 and others) in carcinogenesis and for leveraging tumor vs normal tissue differences for therapy.
Radiation Oncology; Tumor-selective therapies; Cell Stress and Cancer Nanomedicine.